Concomitantly, with their effects on fluid balance, SGLT-2 inhibitors elicit elevations in hematocrit levels among HF patients when incorporated into conventional therapeutic regimens, as evidenced by multiple trials [44,46,48]. This evidence concerns the gene SLC5A2 and hydrops fetalis.